Abstract
Overview
Introduction
The antidyslipidemics market is driven by the statins, which account for 87%
of it. However, as many statins are expected to face patent expiry in the
coming decade their role is expected to change from a driver to that of almost
a resistor. Manufacturers are looking to novel products to protect their
franchise, such as Pfizer's atorvastatin/torcetrapib.
Scope
- Country specific event-driven sales forecasts for the period 2005-14 for
the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
- Patient potential and prescribing trends overview in the antidyslipidemics
market, based on historical sales data and future key events
- Profiles of the country and market-specific issues which will impact
future sales, including generic erosion and class switching
- Case studies presenting Pfizer's strategy with atorvastatin/torcetrapib to
maintain the Lipitor franchize, and the impact of key clinical trials
Report Highlights
Increased knowledge of the metabolic syndrome, fears of statin side effects,
and the increasing data on the importance of HDL have all served to drive
growth of the adjunctive anti-dyslipidemic agent market, by creating an
opportunity for novel as well as combination therapies.
Pfizer's atorvastatin + torcetrapib combination is expected to have a major
impact on the dyslipidemia market and is expected to compete with both
atorvastatin and Vytorin (simvastatin + ezetimibe). While Astra -Zeneca's
Crestor is set to significantly increase in sales due to new safety data.
The expiration of key statin patents could lead to the shrinking of the market
value. The situation will be salvaged by the growing classes of cholesterol
uptake inhibitors and single pill combinations.
Reasons to Purchase
- View independent, event-driven forecasts for key anti-dyslipidemic
products and classes across the seven major markets
- Obtain key opinion leader comments on various topics including prescribing
trends and opinions on currently marketed and late stage development drugs
- Identify the potential impact of clinical trial results, EU healthcare
reform and new product launches on the antidyslipidemic market
View Cart
